Nanobodies^®: proficient tools in diagnostics

References

• Reichert JM. Antibodies to watch in 2010. MAbs2(1), 84–100 (2010).
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat. Biotechnol.23(9), 1105–1116 (2005).
   PubMed Web of Science ®Google Scholar
• Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol.8(5), 600–608 (2008).
   PubMed Web of Science ®Google Scholar
• Barthelemy PA, Raab H, Appleton BA et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem.283(6), 3639–3654 (2008).
   PubMed Web of Science ®Google Scholar
• Wesolowski J, Alzogaray V, Reyelt J et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol.198(3), 157–174 (2009).
   PubMed Web of Science ®Google Scholar
• Dimitrov DS. Engineered CH2 domains (nanoantibodies). MAbs1(1), 26–28 (2009).
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Single domain camel antibodies: current status. J. Biotechnol.74(4), 277–302 (2001).
   PubMed Web of Science ®Google Scholar
• Conrath K, Vincke C, Stijlemans B et al. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J. Mol. Biol.350(1), 112–125 (2005).
   PubMed Web of Science ®Google Scholar
• Desmyter A, Transue TR, Ghahroudi MA et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol.3(9), 803–811 (1996).
   PubMedGoogle Scholar
• De Genst E, Silence K, Decanniere K et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl Acad. Sci. USA103(12), 4586–4591 (2006).
   PubMed Web of Science ®Google Scholar
• Vincke C, Loris R, Saerens D et al. General strategy to humanize a Camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem.284(5), 3273–3284 (2009).
   PubMed Web of Science ®Google Scholar
• Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol.2(2), RESEARCH0004 (2001).
   PubMedGoogle Scholar
• Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig. Drugs10(11), 1212–1224 (2009).
   PubMed Web of Science ®Google Scholar
• Huang L, Reekmans G, Saerens D et al. Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens. Bioelectron.21(3), 483–490 (2005).
   PubMed Web of Science ®Google Scholar
• Rothbauer U, Zolghadr K, Muyldermans S et al. A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol. Cell Proteomics7(2), 282–289 (2008).
   PubMed Web of Science ®Google Scholar
• Saerens D, Stijlemans B, Baral TN et al. Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. J. Immunol. Methods329(1–2), 138–150 (2008).
   PubMedGoogle Scholar
• Verheesen P, Roussis A, de Haard HJ et al. Reliable and controllable antibody fragment selections from camelid non-immune libraries for target validation. Biochim. Biophys. Acta.1764(8), 1307–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Stijlemans B, Conrath K, Cortez-Retamozo V et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J. Biol. Chem.279(2), 1256–1261 (2004).
   PubMed Web of Science ®Google Scholar
• Deckers N, Saerens D, Kanobana K et al. Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. Int. J. Parasitol.39(5), 625–633 (2009).
   PubMed Web of Science ®Google Scholar
• Antoine-Moussiaux N, Saerens D, Desmecht D. Flow cytometric enumeration of parasitaemia and hematologic changes in trypanosoma-infected mice. Acta. Trop.107(2), 139–144 (2008).
   PubMedGoogle Scholar
• Franco EJ, Sonneson GJ, Delegge TJ et al. Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.878(2), 177–186 (2010).
   PubMed Web of Science ®Google Scholar
• Ladenson RC, Crimmins DL, Landt Y, Ladenson JH. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal. Chem.78(13), 4501–4508 (2006).
   PubMed Web of Science ®Google Scholar
• Goldman ER, Anderson GP, Conway J et al. Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex. Anal. Chem.80(22), 8583–8591 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson GP, Goldman ER. TNT detection using llama antibodies and a two-step competitive fluid array immunoassay. J. Immunol. Methods339(1), 47–54 (2008).
   PubMedGoogle Scholar
• Anderson GP, Moreira SC, Charles PT et al. TNT detection using multiplexed liquid array displacement immunoassays. Anal. Chem.78(7), 2279–2285 (2006).
   PubMedGoogle Scholar
• Vo-Dinh T, Kasili P, Wabuyele M. Nanoprobes and nanobiosensors for monitoring and imaging individual living cells. Nanomedicine2(1), 22–30 (2006).
   PubMedGoogle Scholar
• Ryan S, Kell AJ, van Faassen H et al. Single-domain antibody-nanoparticles: promising architectures for increased Staphylococcus aureus detection specificity and sensitivity. Bioconjug. Chem.20(10), 1966–1974 (2009).
   PubMedGoogle Scholar
• Conroy PJ, Hearty S, Leonard P, O’Kennedy RJ. Antibody production, design and use for biosensor-based applications. Semin. Cell Dev. Biol.20(1), 10–26 (2009).
   PubMed Web of Science ®Google Scholar
• Saerens D, Huang L, Bonroy K, Muyldermans S. Antibody fragments as probe in biosensor development. Sensors8(8), 4669–4686 (2008).
   PubMed Web of Science ®Google Scholar
• Pleschberger M, Saerens D, Weigert S et al. An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug. Chem.15(3), 664–671 (2004).
   PubMedGoogle Scholar
• Saerens D, Frederix F, Reekmans G et al. Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal. Chem.77(23), 7547–7555 (2005).
   PubMedGoogle Scholar
• Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J. Nucl. Med.50(1), 2–5 (2009).
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol.23(9), 1137–1146 (2005).
   PubMed Web of Science ®Google Scholar
• van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist12(12), 1379–1389 (2007).
   PubMed Web of Science ®Google Scholar
• Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv.3(1), 53–70 (2006).
   PubMedGoogle Scholar
• Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett.414(3), 521–526 (1997).
   PubMed Web of Science ®Google Scholar
• Huang L, Gainkam LO, Caveliers V et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol. Imaging Biol.10(3), 167–175 (2008).
   PubMed Web of Science ®Google Scholar
• De Groeve K, Deschacht N, De Koninck C et al. Nanobodies as tools for in vivo imaging of specific immune cell types. J. Nucl. Med.51(5), 782–789 (2010).
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Cayre A, Arnould L et al. Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol. Rep.16(6), 1173–1179 (2006).
   PubMed Web of Science ®Google Scholar
• Roovers RC, Laeremans T, Huang L et al. Efficient inhibition of EGFR signaling and of tumor growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol. Immunother.56(3), 303–317 (2007).
   PubMed Web of Science ®Google Scholar
• Vaneycken I, Govaert J, Vincke C et al.In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/Micro-CT. J. Nucl. Med.51(7), 1099–106 (2010).
   PubMed Web of Science ®Google Scholar
• Tijink BM, Laeremans T, Budde M et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer Ther.7(8), 2288–2297 (2008).
   PubMed Web of Science ®Google Scholar
• Gainkam LO, Huang L, Caveliers V et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J. Nucl. Med.49(5), 788–795 (2008).
   PubMed Web of Science ®Google Scholar
• Olichon A, Surrey T. Selection of genetically encoded fluorescent single domain antibodies engineered for efficient expression in Escherichia coli.J. Biol. Chem.282(50), 36314–36320 (2007).
   PubMed Web of Science ®Google Scholar
• Rothbauer U, Zolghadr K, Tillib S et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat. Methods3(11), 887–889 (2006).
   PubMed Web of Science ®Google Scholar
• Kirchhofer A, Helma J, Schmidthals K et al. Modulation of protein properties in living cells using nanobodies. Nat. Struct. Mol. Biol.17(1), 133–138 (2010).
   PubMed Web of Science ®Google Scholar
• Schornack S, Fuchs R, Huitema E et al. Protein mislocalization in plant cells using a GFP-binding chromobody. Plant J.60(4), 744–754 (2009).
   PubMedGoogle Scholar
• Cruz HJ, Rosa CC, Oliva AG. Immunosensors for diagnostic applications. Parasitol. Res.88(13 Suppl. 1), S4–S7 (2002).
   PubMed Web of Science ®Google Scholar
• Luppa PB, Sokoll LJ, Chan DW. Immunosensors – principles and applications to clinical chemistry. Clin. Chim. Acta.314(1–2), 1–26 (2001).
   PubMed Web of Science ®Google Scholar
• Alvarez-Rueda N, Behar G, Ferre V et al. Generation of llama single-domain antibodies against methotrexate, a prototypical hapten. Mol. Immunol.44(7), 1680–1690 (2007).
   PubMed Web of Science ®Google Scholar
• Yau KY, Groves MA, Li S et al. Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J. Immunol. Methods281(1–2), 161–175 (2003).
   PubMed Web of Science ®Google Scholar
• Doyle PJ, Arbabi-Ghahroudi M, Gaudette N et al. Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol. Mol. Immunol.45(14), 3703–3713 (2008).
   PubMed Web of Science ®Google Scholar
• Sonneson GJ, Horn JR. Hapten-induced dimerization of a single-domain VHH camelid antibody. Biochemistry48(29), 6693–6695 (2009).
   PubMedGoogle Scholar
• Choi JW, Oh BK, Kim YK, Min J. Nanotechnology in biodevices. J. Microbiol. Biotechnol.17(1), 5–14 (2007).
   PubMedGoogle Scholar
• Jain KK. Applications of nanobiotechnology in clinical diagnostics. Clin. Chem.53(11), 2002–2009 (2007).
   PubMed Web of Science ®Google Scholar
• Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood–brain barrier endothelium. FASEB J.16(2), 240–242 (2002).
   PubMed Web of Science ®Google Scholar
• Tanha J, Muruganandam A, Stanimirovic D. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol. Med.89, 435–449 (2003).
   PubMedGoogle Scholar